TC
SPRY icon

Tannin Capital’s ARS Pharmaceuticals SPRY Stock Holding History

Tannin Capital’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$132K Sell
16,440
-2,153
-12% -$18.5K 0.09% 169
2026
Q1 		$149K Buy
18,593
+5,527
+42% +$53K 0.11% 152
2025
Q4 		$152K Buy
+13,066
New +$127K 0.14% 133

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Tannin Capital's SPRY Position: Q2 2026 in Review

Tannin Capital reduced its ARS Pharmaceuticals (SPRY) stake by 12% in Q2 2026, selling an estimated $18.5K and leaving 16,440 shares worth $132K. The position accounts for 0.09% of the portfolio, ranked #169.

Tannin Capital first reported a position in SPRY in Q4 2025 and has held it in 3 quarters since. The position peaked at $152K in Q4 2025. 206 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Tannin Capital held 16,440 shares of ARS Pharmaceuticals worth $132K as of Q2 2026.
  • Tannin Capital sold 2,153 ARS Pharmaceuticals shares in Q2 2026, an estimated $18.5K.
  • ARS Pharmaceuticals made up 0.09% of Tannin Capital's portfolio in Q2 2026, its #169 holding.
  • Tannin Capital first reported a position in ARS Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Tannin Capital's ARS Pharmaceuticals position peaked at $152K in Q4 2025.
  • 206 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Tannin Capital's 13F filing for Q2 2026, filed 4 Aug 2026.